Thank you for your interest in HPTN 083. The main purpose of this study is to evaluate a medication called cabotegravir (CAB) for Pre-exposure Prophylaxis (PrEP) against HIV infection. Currently, Truvada is the only approved medication for PrEP, but early studies with CAB have been promising. CAB is available in the form of a pill and as an injection (shot). In this study, researchers will be evaluating the injectable form of CAB against Truvada. Researchers do not yet know if this injectable drug will work to protect people from getting HIV or if it will work just as well as Truvada. In this study, you will take pills every day, and you will get a shot every 8 weeks.
This study is being offered to 4500 HIV-uninfected men who have sex with men (MSM) and transgender women (TGW) that have sex with men in Asia, North and South America, and South Africa. Before anyone decides whether to join the study, they should learn more about the study, the risks and benefits of participation, and the amount of time involved.
Everyone’s participation is voluntary, and even after deciding to take part in the study, study participants can choose to leave the study at any time.
A description of this study is available at Clinical Trials Site as required by US law.
The Principal Investigator is Richard M. Novak MD, Chief of Infectious Diseases, Department of Medicine, University of Illinois at Chicago.
If you are interested in this study, please contact Project WISH at 312-413-5897 or email at [email protected].